Tacrolimus limits polymorphonuclear leucocyte accumulation and protects against myocardial ischaemia- reperfusion injury

J Mol Cell Cardiol. 2000 Mar;32(3):429-40. doi: 10.1006/jmcc.1999.1089.

Abstract

Intercellular adhesion molecule-1 (ICAM-1) plays an important role in the pathogenesis of either human and experimental myocardial ischaemia. Tacrolimus, formerly known as FK506, has been previously shown to display cardioprotective effects on experimental ischaemia/reperfusion-induced myocardial damage. This study investigated whether cardioprotection induced by tacrolimus in myocardial ischaemia-reperfusion (MI/R) injury might be due to inhibition of the nuclear factor kappa B (NF- kappaB) that in turn causes reduced cardiac ICAM-1 expression and blunted polymorphonuclear leukocyte accumulation. Anaesthetized rats were subjected to total occlusion (45 min) of the left main coronary artery followed by 5 h reperfusion (MI/R). Sham myocardial ischaemia-reperfusion rats (Sham MI/R) were used as controls. Myocardial necrosis, myocardial myeloperoxidase activity, serum creatine kinase (CK) activity, cardiac mRNA for ICAM-1 reverse-transcriptase polymerase chain reaction, the inhibitory protein of NF- kappaB I kappaB alpha (Western blot analysis) in the myocardium-at-risk, and left ventricle d P/d t(max)were evaluated. Myocardial ischaemia plus reperfusion in untreated rats produced marked myocardial necrosis, increased serum CK activity and myeloperoxidase activity (MPO, a marker of leukocyte accumulation) both in the area at risk and in the necrotic area, and reduced the left ventricle dP/d t(max). Furthermore, inhibitory protein I kappaB alpha levels decreased, and cardiac mRNA for ICAM-1 increased, after 0.5 and 5 h of reperfusion, respectively. Administration of tacrolimus (25, 50 and 100microg/kg as an i.v. infusion 5 min after reperfusion) lowered myocardial necrosis and myeloperoxidase activity in the area at risk and in necrotic area, decreased serum CK activity, increased left ventricle dP/d t(max), reduced the loss the of inhibitory protein I kappaB alpha and blunted the message for ICAM-1. The present data suggest that tacrolimus blocks the early activation of the transcription factor NF- kappaB, suppresses ICAM-1 gene activation, reduces leukocyte accumulation and protects against myocardial ischaemia-reperfusion injury.

MeSH terms

  • Animals
  • Creatine Kinase / blood
  • Gene Expression Regulation / drug effects
  • Hemodynamics
  • Immunosuppressive Agents / administration & dosage
  • Immunosuppressive Agents / metabolism*
  • Intercellular Adhesion Molecule-1 / genetics*
  • Male
  • Myocardial Infarction / pathology
  • Myocardial Ischemia / immunology*
  • Myocardial Ischemia / pathology
  • Myocardial Reperfusion Injury / prevention & control*
  • NF-kappa B / antagonists & inhibitors*
  • Neutrophils / immunology*
  • Peroxidase / metabolism
  • RNA, Messenger
  • Rats
  • Rats, Sprague-Dawley
  • Tacrolimus / administration & dosage
  • Tacrolimus / metabolism*
  • Transcriptional Activation

Substances

  • Immunosuppressive Agents
  • NF-kappa B
  • RNA, Messenger
  • Intercellular Adhesion Molecule-1
  • Peroxidase
  • Creatine Kinase
  • Tacrolimus